Basilea Pharmaceutica Past Earnings Performance
Past criteria checks 3/6
Basilea Pharmaceutica has been growing earnings at an average annual rate of 62.1%, while the Biotechs industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 13.2% per year. Basilea Pharmaceutica's return on equity is 31.5%, and it has net margins of 17.3%.
Key information
62.08%
Earnings growth rate
62.48%
EPS growth rate
| Biotechs Industry Growth | 18.93% |
| Revenue growth rate | 13.17% |
| Return on equity | 31.45% |
| Net Margin | 17.32% |
| Next Earnings Update | 18 Aug 2026 |
Recent past performance updates
Recent updates
Emerging Markets And Drug Resistance Will Drive Global Expansion
The consensus Analyst Price Target for Basilea Pharmaceutica has increased to CHF90.42, reflecting a higher future P/E multiple despite slightly lower forecast revenue growth. What's in the News Basilea raised full-year 2025 revenue guidance to CHF 225 million (up 8%) but lowered expected operating result to CHF 50 million from CHF 62 million.Basilea Pharmaceutica (VTX:BSLN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Despite announcing strong earnings, Basilea Pharmaceutica AG's ( VTX:BSLN ) stock was sluggish. We think that the...Emerging Markets And Drug Resistance Will Drive Global Expansion
Key Takeaways Expanding global sales of key anti-infective drugs and successful commercialization partnerships are driving top-line growth and increased royalty income. Strategic pipeline development, acquisitions, and a partnership-driven model support profit growth, regulatory momentum, and future market expansion.Benign Growth For Basilea Pharmaceutica AG (VTX:BSLN) Underpins Its Share Price
Basilea Pharmaceutica AG's ( VTX:BSLN ) price-to-sales (or "P/S") ratio of 3.4x might make it look like a buy right now...Shareholders Will Probably Hold Off On Increasing Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For The Time Being
Key Insights Basilea Pharmaceutica's Annual General Meeting to take place on 16th of April CEO David Veitch's total...Estimating The Intrinsic Value Of Basilea Pharmaceutica AG (VTX:BSLN)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Basilea Pharmaceutica fair value estimate is CHF41.11 Current...There May Be Underlying Issues With The Quality Of Basilea Pharmaceutica's (VTX:BSLN) Earnings
Unsurprisingly, Basilea Pharmaceutica AG's ( VTX:BSLN ) stock price was strong on the back of its healthy earnings...Basilea Pharmaceutica (VTX:BSLN) Could Easily Take On More Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now
Key Insights Basilea Pharmaceutica's Annual General Meeting to take place on 24th of April Total pay for CEO David...Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)
Basilea Pharmaceutica AG ( VTX:BSLN ) just released a solid earnings report, and the stock displayed some strength...Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)
Market forces rained on the parade of Basilea Pharmaceutica AG ( VTX:BSLN ) shareholders today, when the analysts...Revenue & Expenses Breakdown
How Basilea Pharmaceutica makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 232 | 40 | 35 | 0 |
| 30 Sep 25 | 234 | 56 | 34 | 0 |
| 30 Jun 25 | 236 | 73 | 33 | 0 |
| 31 Mar 25 | 222 | 75 | 32 | 0 |
| 31 Dec 24 | 209 | 78 | 31 | 0 |
| 30 Sep 24 | 179 | 38 | 31 | 0 |
| 30 Jun 24 | 149 | -1 | 31 | 0 |
| 31 Mar 24 | 153 | 5 | 31 | 0 |
| 31 Dec 23 | 158 | 10 | 31 | 0 |
| 30 Sep 23 | 166 | 33 | 30 | 0 |
| 30 Jun 23 | 175 | 56 | 29 | 0 |
| 31 Mar 23 | 161 | 34 | 29 | 0 |
| 31 Dec 22 | 148 | 12 | 29 | 0 |
| 30 Sep 22 | 150 | 6 | 29 | 0 |
| 30 Jun 22 | 152 | 1 | 29 | 0 |
| 31 Mar 22 | 150 | -3 | 28 | 0 |
| 31 Dec 21 | 148 | -7 | 28 | 0 |
| 30 Sep 21 | 130 | -26 | 28 | 0 |
| 30 Jun 21 | 112 | -45 | 27 | 0 |
| 31 Mar 21 | 120 | -30 | 28 | 0 |
| 31 Dec 20 | 128 | -15 | 28 | 0 |
| 30 Sep 20 | 134 | -6 | 27 | 0 |
| 30 Jun 20 | 141 | 3 | 27 | 0 |
| 31 Mar 20 | 137 | -10 | 28 | 0 |
| 31 Dec 19 | 134 | -22 | 29 | 0 |
| 30 Sep 19 | 135 | -23 | 29 | 0 |
| 30 Jun 19 | 136 | -24 | 30 | 0 |
| 31 Mar 19 | 134 | -28 | 30 | 0 |
| 31 Dec 18 | 133 | -31 | 30 | 0 |
| 30 Sep 18 | 124 | -26 | 32 | 0 |
| 30 Jun 18 | 115 | -21 | 33 | 0 |
| 31 Mar 18 | 108 | -20 | 42 | 0 |
| 31 Dec 17 | 102 | -19 | 52 | 0 |
| 30 Sep 17 | 92 | -32 | 57 | 0 |
| 30 Jun 17 | 82 | -44 | 62 | 0 |
| 31 Mar 17 | 74 | -48 | 59 | 0 |
| 31 Dec 16 | 66 | -51 | 56 | 0 |
| 30 Sep 16 | 62 | -55 | 57 | 0 |
| 30 Jun 16 | 58 | -59 | 57 | 0 |
| 31 Mar 16 | 55 | -61 | 56 | 0 |
| 31 Dec 15 | 53 | -62 | 54 | 0 |
| 30 Sep 15 | 50 | -57 | 48 | 0 |
| 30 Jun 15 | 47 | -52 | 42 | 0 |
Quality Earnings: BSLN has high quality earnings.
Growing Profit Margin: BSLN's current net profit margins (17.3%) are lower than last year (37.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BSLN has become profitable over the past 5 years, growing earnings by 62.1% per year.
Accelerating Growth: BSLN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BSLN had negative earnings growth (-48.1%) over the past year, making it difficult to compare to the Biotechs industry average (4.2%).
Return on Equity
High ROE: BSLN's Return on Equity (31.5%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/04 16:42 |
| End of Day Share Price | 2026/06/04 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Basilea Pharmaceutica AG is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brigitte de Lima | BofA Global Research |
| Brian White | Calvine Partners LLP |
| Andrew Keith | Calvine Partners LLP |